ライフサイエンスコーパス: quetiapine

1 stent with the known tolerability profile of quetiapine.

2 one, and risperidone was more effective than quetiapine.

3 s for clozapine, olanzapine, risperidone, or quetiapine.

4 idone and typical neuroleptics, and low with quetiapine.

5 to clozapine, and only 14% were switched to quetiapine.

6 ent with lithium, valproate, olanzapine, and quetiapine.

7 likely in participants taking 300 mg/day of quetiapine.

8 n is variable with the clearest evidence for quetiapine.

9 Tests with quetiapine (0 vs. 7.5 mg/kg) in a within-subject design

10 nterval), olanzapine was more effective than quetiapine (-0.29; -0.56 to -0.02), haloperidol (-0.29;

11 speridone=28.0%, typical neuroleptics=14.5%, quetiapine=0.0%).

12 o treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/da

13 o treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/da

14 ol injection=62, olanzapine=144, placebo=75, quetiapine=125, risperidone=124, UC=30 and ziprasidone=3

15 ved olanzapine, 16% of patients who received quetiapine, 18% of patients who received risperidone, an

16 .02) with an NNH of 40 (95% CI, 21-312); and quetiapine, 2.0% (95% CI, 0.7%-3.3%; P < .01) with an NN

17 per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5

18 psychotic (olanzapine, 7.5-30 mg/day [N=66]; quetiapine, 200-800 mg/day [N=63]; risperidone, 1.5-6.0

19 en groups, more somnolence was observed with quetiapine (22% vs. 11%; p = .66).

20 d to olanzapine, 26% of patients assigned to quetiapine, 29% of patients assigned to risperidone, and

21 onths) and olanzapine (6.3 months) than with quetiapine (4.0 months) and ziprasidone (2.8 months).

22 total of 1,953 patients received open-label quetiapine (400-800 mg/day in flexible, divided doses) w

23 Patients were randomized to receive quetiapine 50 mg every 12 hrs or placebo.

24 ne (409; 95% CI, 345-483 per 10000 PYAR), or quetiapine (582; 95% CI, 489-692 per 10000 PYAR).

25 ridone extended-release, 9 or 12 mg/day, and quetiapine, 600 or 800 mg/day.

26 erphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone,

27 nd risperidone (26.7 weeks) as compared with quetiapine (9.1 weeks) and placebo (9.0 weeks) (P=0.002)

28 Quetiapine added to as-needed haloperidol results in fas

29 This dose of quetiapine also blocked the PPI-disruptive effects of ph

30 ole), abnormal metabolic laboratory results (quetiapine and OFC), and weight gain (all four drugs, es

31 ntified between patients receiving high-dose quetiapine and placebo for both primary efficacy variabl

32 Short-term treatment with both quetiapine and risperidone resulted in improvements in s

33 han the atypical drugs, including clozapine, quetiapine and risperidone.

34 done and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time u

35 (N=184), olanzapine was more effective than quetiapine and ziprasidone, and risperidone was more eff

36 zophrenia were 0.19 for olanzapine, 0.34 for quetiapine, and 0.22 for risperidone.

37 e battery were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidone.

38 (SD=5.3) for olanzapine, 506 mg (SD=215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone.

39 oses were 11.7 mg for olanzapine, 506 mg for quetiapine, and 2.4 mg for risperidone.

40 liperidone extended-release, 66.7% (106/159) quetiapine, and 63.8% (51/80) placebo.

41 ively, in the paliperidone extended-release, quetiapine, and placebo groups.

42 e events with paliperidone extended-release, quetiapine, and placebo, respectively, were tremor (13.9

43 Olanzapine, quetiapine, and risperidone all produced significant imp

44 Olanzapine, quetiapine, and risperidone demonstrated comparable effe

45 atment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients early in the cou

46 t of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients wit

47 sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function i

48 n antipsychotics (eg, clozapine, olanzapine, quetiapine, and risperidone) are associated with an incr

49 up, the atypical antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-response incr

50 eration antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week tria

51 r an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid and its deri

52 were 68.4%, 70.9%, and 71.4% for olanzapine, quetiapine, and risperidone, respectively.

53 ute change in mortality risk for olanzapine, quetiapine, and risperidone.

54 le, olanzapine/fluoxetine combination (OFC), quetiapine, and risperidone.

55 udies comprising 66 risperidone, olanzapine, quetiapine, and ziprasidone arms including 7264 patients

56 showed superior efficacy versus haloperidol, quetiapine, and ziprasidone.

57 ine; 10,970 [48.4%], olanzapine; 955 [4.2%], quetiapine; and 9,903 [43.7%], risperidone; 387 patients

58 , that is, adding a second treatment (adding quetiapine, aripiprazole, buspirone alpha2delta ligand a

59 ychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloper

60 These findings suggest quetiapine as a single agent is effective in treating mi

61 rescribed lithium, valproate, olanzapine, or quetiapine as maintenance mood stabilizer treatment.

62 7 prescribed olanzapine, and 1376 prescribed quetiapine as maintenance mood stabilizer treatment.

63 Initiation of quetiapine as treatment for severe anxiety that was unre

64 S) between paliperidone extended-release and quetiapine at the 2-week monotherapy phase endpoint.

65 ents who received clozapine, olanzapine, and quetiapine, but not risperidone.

66 (n = 13), and underwent four-week rTMS with quetiapine concomitantly.

67 Quetiapine demonstrated the lowest placental passage of

68 paliperidone extended-release compared with quetiapine despite similar use of additive therapy (pred

69 a 1:1 ratio to receive treatment with either quetiapine (dose range: 200-800 mg/day) or risperidone (

70 When compared directly with quetiapine, dose-adjusted mortality risk was increased w

71 , weight gain (51%), and insomnia (38%); for quetiapine, drowsiness (58%), increased sleep hours (42%

72 ] of 57 patients; estimated 63.5%) than with quetiapine-ER (15 [30%] of 50; estimated 31.3%; p=0.0021

73 tly higher for aripiprazole (97.1%) than for quetiapine-ER (89.2%; p=0.012).

74 ility, of whom 113 were randomly assigned to quetiapine-ER (n=55) or aripiprazole (n=58).

75 Weight gain was more rapid with quetiapine-ER (p=0.0008), with an adjusted mean weight g

76 treatment with target doses of 600 mg/day of quetiapine-ER (starting from 50 mg/day) or 20 mg/day of

77 events were tremor (42 [79%] patients in the quetiapine-ER group vs 52 [91%] patients in the aripipra

78 ved at weeks 2, 4, and 12, respectively, for quetiapine-ER in 43 [83%] of 52, 40 [83%] of 48, and 34

79 ATION: This first head-to-head comparison of quetiapine-ER versus aripiprazole in early-onset psychos

80 Quetiapine-ER was associated with more metabolic adverse

81 y and safety of quetiapine-extended release (quetiapine-ER) versus aripiprazole in children and adole

82 weeks (adjusted mean change -5.05 [5.46] for quetiapine-ER, -6.21 [5.42] for aripiprazole; p=0.98), b

83 aimed to compare the efficacy and safety of quetiapine-extended release (quetiapine-ER) versus aripi

84 with paliperidone extended-release than with quetiapine from day 5 (-11.4 versus -8.2) through the mo

85 fumarate (< or = 750 mg/d), n = 96; low-dose quetiapine fumarate (< or = 250 mg/d), n = 94; or placeb

86 mized to 6 weeks of treatment with high-dose quetiapine fumarate (< or = 750 mg/d), n = 96; low-dose

87 , risperidone (1994), olanzapine (1996), and quetiapine fumarate (1997)-offer a decrease in serious a

88 Quetiapine fumarate (Seroquel [ICI 204,636]) is an atypi

89 , 1.58; 95% CI, 1.21-2.07; P = .001) but not quetiapine fumarate or olanzapine.

90 es, insulin, and insulin resistance, whereas quetiapine fumarate was associated with significantly hi

91 antipsychotics (risperidone, olanzapine, and quetiapine fumarate).

92 ive treatment with olanzapine, perphenazine, quetiapine fumarate, or risperidone for up to 18 months

93 domly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo with the op

94 isperidone, and 2.16 (95% CI, 1.88-2.48) for quetiapine fumarate.

95 ose value > or =126 mg/dl were higher in the quetiapine group (12.6% versus 5.4%; 18.44 versus 9.56 p

96 ratio=2.54, p=0.007) and the moderate-dosage quetiapine group (hazard ratio=2.37, p=0.011) than for t

97 ignificantly shorter for both the low-dosage quetiapine group (hazard ratio=2.54, p=0.007) and the mo

98 Fewer patients in the quetiapine group experienced a mood event compared with

99 Participants in the low-dosage quetiapine group had significant improvement on the Zana

100 al scores were significantly greater for the quetiapine group than for the placebo group.

101 o completed the study, 82% in the low-dosage quetiapine group were rated as "responders," compared wi

102 atment phase was 67% (67% for the low-dosage quetiapine group, 58% for the moderate-dosage quetiapine

103 uetiapine group, 58% for the moderate-dosage quetiapine group, and 79% for the placebo group).

104 pothyroidism occurred more frequently in the quetiapine group, as did discontinuations due to adverse

105 Participants treated with 150 mg/day of quetiapine had a significant reduction in the severity o

106 ium, those taking valproate, olanzapine, and quetiapine had reduced rates of chronic kidney disease s

107 (hazard ratio=1.15); the diabetes risks for quetiapine (hazard ratio=1.20) and risperidone (hazard r

108 zapine HR 0.32; 95% CI 0.14-0.76; p = 0.008, quetiapine HR 0.23; 95% CI 0.07-0.73; p = 0.013) were al

109 zapine HR 0.57; 95% CI 0.45-0.71; p < 0.001, quetiapine HR 0.62; 95% CI 0.47-0.80; p < 0.001).

110 zapine HR 1.84; 95% CI 1.47-2.30; p < 0.001, quetiapine HR 1.67; 95% CI 1.24-2.20; p < 0.001) than in

111 peridone (HR = 1.60, 95% CI: 1.19, 2.14), or quetiapine (HR = 1.67, 95% CI: 1.01, 2.76).

112 l flupentixol (HR, 0.92; 95% CI, 0.74-1.14), quetiapine (HR, 0.91; 95% CI, 0.83-1.00), and oral perph

113 valproate (HR, 1.32; 95% CI, 1.10-1.58) and quetiapine (HR, 1.34; 95% CI, 1.07-1.69) but not olanzap

114 low and moderate dosages of extended-release quetiapine in adults with borderline personality disorde

115 th weight gain in women, with olanzapine and quetiapine in particular, and with unfavorable change in

116 buted to use of olanzapine, risperidone, and quetiapine in patients taking these medications.

117 s compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizop

118 Greater improvements were also observed for quetiapine in scores on the Davidson Trauma Scale, CGI s

119 mild and expected based on prior studies of quetiapine in this and other patient population.

120 I deficits after BLA lesions are reversed by quetiapine, in a manner that is sustained beyond its acu

121 Quetiapine is an atypical antipsychotic agent with a com

122 Quetiapine is an effective antipsychotic with a favorabl

123 eive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean dose, 56.5 mg per day), risperidone (me

124 3%), risperidone (mean=49.2%, SD=33.9%), and quetiapine (mean=23.8%, SD=11.0%).

125 any reason: olanzapine (median, 8.1 weeks), quetiapine (median, 5.3 weeks), risperidone (median, 7.4

126 for clozapine (median=10.5 months) than for quetiapine (median=3.3), or risperidone (median=2.8), bu

127 combined with quetiapine was not superior to quetiapine monotherapy in improving depressive symptoms

128 o-controlled trial to assess the efficacy of quetiapine monotherapy in the treatment of posttraumatic

129 nt in depressive symptoms over 12 weeks than quetiapine monotherapy plus lamotrigine placebo.

130 Quetiapine monotherapy was efficacious in the treatment

131 proate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer tre

132 45), by 6.1 kg (95% CI, 4.9 to 7.2 kg) with quetiapine (n = 36), by 5.3 kg (95% CI, 4.8 to 5.9 kg) w

133 signed to treatment with olanzapine (N=133), quetiapine (N=134), or risperidone (N=133).

134 , risperidone (N=80), olanzapine (N=63), and quetiapine (N=28) over a 3-month period were identified

135 olanzapine (N=319), risperidone (N=271), or quetiapine (N=94), the authors examined the impact of be

136 ly received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).

137 , olanzapine [N=31], risperidone [N=22], and quetiapine [N=9]).

138 idone (odds ratio: 1.53, 95% CI: 1.43-1.64), quetiapine (odds ratio: 1.52, 95% CI: 1.40-1.65), olanza

139 ncluding akathisia (aripiprazole), sedation (quetiapine, OFC, and aripiprazole), abnormal metabolic l

140 sed in the treatment of affective disorders (quetiapine, olanzapine, and semisodium valproate) during

141 Lithium, quetiapine, olanzapine, bupropion, and carbamazepine wer

142 ol, clozapine, aripiprazole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all

143 antipsychotic drugs (APDs), e.g., clozapine, quetiapine, olanzapine, risperidone, and ziprasidone, ha

144 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carb

145 Future studies should evaluate the effect of quetiapine on mortality, resource utilization, post-inte

146 d the effects of (short-term) treatment with quetiapine on the risky decision-making of healthy human

147 omly assigned to double-blind treatment with quetiapine or placebo, in combination with lithium or di

148 e randomly assigned to treatment with either quetiapine or placebo.

149 with clozapine than in patients treated with quetiapine or risperidone but not olanzapine.

150 bacco users) with schizophrenia treated with quetiapine or risperidone monotherapy were randomized to

151 ymptom improvement, in patients treated with quetiapine or ziprasidone.

152 NNT, 7), OFC (OR, 1.30, 95% CI, 0.87-1.93), quetiapine (OR, 1.53, 95% CI, 1.17-2.0; NNT, 10), and ri

153 .48-2.73), OFC (OR, 1.42; 95% CI, 1.01-2.0), quetiapine (OR, 1.79; 95% CI, 1.33-2.42), and risperidon

154 ho initiated use of olanzapine, risperidone, quetiapine, or haloperidol in 1999-2001 after at least 3

155 h an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or valproic acid and its der

156 reatment with paliperidone extended-release, quetiapine, or placebo.

157 Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks.

158 g the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate

159 on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly assigned to swi

160 ly longer for clozapine than for olanzapine, quetiapine, or risperidone.

161 There is no association with olanzapine, quetiapine, or risperidone.

162 in children taking olanzapine, risperidone, quetiapine, or valproate.

163 2), 0.25 for perphenazine (P<.001), 0.18 for quetiapine (P<.001), 0.26 for risperidone (P<.001), and

164 y longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but

165 Compared with quetiapine, paliperidone extended-release improved sympt

166 med to determine if combination therapy with quetiapine plus lamotrigine leads to greater improvement

167 authors evaluated the efficacy and safety of quetiapine plus lithium or divalproex in the prevention

168 In patients stabilized on quetiapine plus lithium or divalproex, continued treatme

169 The combination of lamotrigine plus quetiapine potentially offers improved outcomes for peop

170 d to be >/= 15.5 mug/capita/day, followed by quetiapine (QTP; 8.51 mug/capita/day), citalopram (CLP;

171 (relative risk=0.91, 95% CI=0.78-1.06), and quetiapine (relative risk=0.73, 95% CI=0.67-0.80).

172 Subjects treated with quetiapine required fewer days of as-needed haloperidol

173 With olanzapine and quetiapine, respectively, mean levels increased signific

174 d exposures of doxazosin, tamsulosin, and/or quetiapine, resulting in additional alpha-adrenergic blo

175 racetam, amantadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do not appear to

176 o atypical antipsychotic drugs, specifically quetiapine, risperidone, and olanzapine, are known to ca

177 zed, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who

178 Quetiapine, risperidone, and ziprasidone use were not as

179 ent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

180 napine, iloperidone, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone.

181 ed, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up to 36 weeks.

182 to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo.

183 ssigned to receive olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone for up to 18 mon

184 who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B

185 zole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, risperidone long-acting injecti

186 BPRS positive-symptom cluster score showing quetiapine's consistency in reducing positive symptoms.

187 e and risperidone showed declining rates and quetiapine showed an increase during the early-warning p

188 de was superior for reduction of symptoms to quetiapine (SMD -0.25, 95% CI -0.50 to -0.01).

189 eatment with lithium was superior to that of quetiapine, suggesting the importance of having lithium

190 e randomly assigned to receive 150 mg/day of quetiapine (the low-dosage group; N=33), 300 mg/day of q

191 (the low-dosage group; N=33), 300 mg/day of quetiapine (the moderate-dosage group; N=33), or placebo

192 s than 1 year of olanzapine, risperidone, or quetiapine therapy.

193 Addition of lamotrigine to quetiapine treatment improved outcomes.

194 Quetiapine treatment was associated with a marked tenden

195 Olanzapine and quetiapine treatments were significantly associated with

196 , N=1,235), olanzapine (two studies, N=610), quetiapine (two studies, N=386), amisulpride (one study,

197 < .01) with an NNH of 31 (95% CI, 21-62) for quetiapine users.

198 CI, 1.12-1.74 for valproate, olanzapine, or quetiapine vs lithium) and PS matching (HR, 1.51; 95% CI

199 ) and intensive care unit length of stay (16 quetiapine vs. 16 days) were similar, subjects treated w

200 Whereas mortality (11% quetiapine vs. 17%) and intensive care unit length of st

201 be discharged home or to rehabilitation (89% quetiapine vs. 56%; p =.06).

202 r, a pooled analysis of 3 trials showed that quetiapine was associated with a 26% greater likelihood

203 Quetiapine was associated with a shorter time to first r

204 Quetiapine was associated with benefits in the treatment

205 Of 280 patients in whom the efficacy of quetiapine was evaluated, 159 (42% of those receiving hi

206 Quetiapine was increased every 24 hrs (50 to 100 to 150

207 findings indicated active rTMS combined with quetiapine was not superior to quetiapine monotherapy in

208 Once a therapeutic dose of quetiapine was reached, ventilator support was removed w

209 After a 1-week placebo run-in, quetiapine was started at a daily dosage of 25 mg and in

210 tive symptoms was less consistent; high-dose quetiapine was superior on the Modified Scale for the As

211 Quetiapine was the least prescribed of the newer drugs.

212 The atypical antipsychotic quetiapine was used to reverse PPI deficits after basola

213 Quetiapine was well tolerated and did not induce extrapy

214 5% weight gain on valproate, olanzapine, and quetiapine were higher (valproate HR 1.62; 95% CI 1.31-2

215 16 days) were similar, subjects treated with quetiapine were more likely to be discharged home or to

216 and patients who had stable prescriptions of quetiapine were the most likely to be switched (37%).

217 as prescribed more often than risperidone or quetiapine, which were prescribed more often than other

218 of drugs to treat parkinsonian symptoms and quetiapine with less akathisia than haloperidol, aripipr

219 Twenty participants received 150 mg of quetiapine XL for 7 d, whereas 20 age- and IQ-matched pa